While Agios Pharmaceuticals Inc. waits to hear from the FDA about its acute myeloid leukemia (AML) therapy's NDA, the company is mulling the prospect of an eventual label "in newly diagnosed patients unfit for any therapy," CEO David Schenkein said, and it's ambitions of that caliber that helped the company raise $475 million in a public offering set to close Tuesday.